Skip to content

13F-HR filed by NOVO HOLDINGS A/S

NOVO HOLDINGS A/S filed this 13F-HR for the quarter ended 2017-09-30, filed 2017-11-14, with 17 holding rows worth $768,311,000.

Accession
0000950123-17-010699
Filed
2017-11-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q3 2017

A holdings report, 17 entries on the cover page, a total value of $768,311,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $768,329,000 with VALUE read as thousands by filing date, 13F file number 028-16231. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
INOGEN INC45780L104COM3,549,320$337,540,000thousands by filing date
ACCELERON PHARMA INC00434H108COM1,553,937$57,993,000thousands by filing date
DERMIRA INC24983L104COM1,921,580$51,883,000thousands by filing date
CORVUS PHARMACEUTICALS INC221015100COM3,244,046$51,710,000thousands by filing date
ANAPTYSBIO INC032724106COM1,190,604$41,612,000thousands by filing date
AKEBIA THERAPEUTICS INC00972D105COMMON STOCK1,887,535$37,128,000thousands by filing date
FLEXION THERAPEUTICS INC33938J106COM1,500,000$36,270,000thousands by filing date
RA PHARMACEUTICALS INC74933V108COM2,031,562$29,661,000thousands by filing date
MERUS N VN5749R100COM1,410,417$28,025,000thousands by filing date
NABRIVA THERAPEUTICS PLCG63637105SHS2,903,800$23,782,000thousands by filing date
REATA PHARMACEUTICALS INC75615P103CL A592,794$18,436,000thousands by filing date
KALVISTA PHARMACEUTICALS INC483497103COM2,725,283$18,341,000thousands by filing date
INVUITY INC46187J205COM NEW1,363,848$12,138,000thousands by filing date
VERONA PHARMA PLC925050106SPONSORED ADS740,740$11,370,000thousands by filing date
WRIGHT MED GROUP N VN96617126RIGHT 03/01/20194,622,032$7,164,000thousands by filing dateprincipal
CRISPR THERAPEUTICS AG NAMEN AKTH17182108Stock223,317$3,991,000thousands by filing date
APOLLO ENDOSURGERY INC03767D108COM274,472$1,285,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0000950123-17-010699this filing2017-11-14acceptance time not in the bulk data set